Hadasit portfolio co receives approval for colon cancer test
Biomarker Technologies has also received a loan to complete its breast cancer testing trial.
Hadasit Bio also announced that it is extending a NIS 1.2 million convertible loan to Biomarker to complete its previous clinical trial, to identify and monitor breast cancer through blood tests, and to fund this latest colon cancer testing trial.
Biomarker develops molecular diagnostic tools based on innovative biomarkers to detect early stage cancer through routine blood tests. Hadasit hold 87.5% of Biomarker.
Hadasit's Bio's share price rose 1.13% in afternoon trading to NIS 0.98.
Published by Globes, Israel business news - www.globes-online.com - on March 6, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options